Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state
Open accessThe DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Transcriptional reprogramming of proliferative melanoma cells into a phenotypically distinct invasive cell subpopulation is a critical event at the origin of metastatic spreading. Here we generate transcriptome, open chromatin and histone modification maps of melanoma cultures; and integrate this data with existing transcriptome and DNA methylation profiles from tumour biopsies to gain insight into the mechanisms underlying this key reprogramming event. This shows thousands of genomic regulatory regions underlying the proliferative and invasive states, identifying SOX10/MITF and AP-1/TEAD as regulators, respectively. Knockdown of TEADs shows a previously unrecognized role in the invasive gene network and establishes a causative link between these transcription factors, cell invasion and sensitivity to MAPK inhibitors. Using regulatory landscapes and in silico analysis, we show that transcriptional reprogramming underlies the distinct cellular states present in melanoma. Furthermore, it reveals an essential role for the TEADs, linking it to clinically relevant mechanisms such as invasion and resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“among the SALL4-HDAC2 targets upregulated upon SALL4 knockdown, we found integrins (ITGB1, ITGA6, ITGA4), N-cadherin (CDH2), TGFBR2, VEGFR-1, PDGFC, LOXL2, MAPK8, and many others which are associated with invasive melanoma phenotypes40–42”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SALL4-regulated genes showed a significant enrichment and positive correlation with published invasiveness signatures40–42, while they significantly anti-correlated with their corresponding proliferation signatures40–42”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Cited by
YAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
Shaffer, S. M., Dunagin, M. C., Torborg, S. R., Torre, E. A., Emert, B., Krepler, C., Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017) · Nature · doi:10.1038/nature22794 · Cited by 1,218
Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine
Moya, I. M., & Halder, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0086-y · Cited by 981
Self-citationSCENIC+: single-cell multiomic inference of enhancers and gene regulatory networks
Bravo González-Blas, C., De Winter, S., Hulselmans, G., Hecker, N., Matetovici, I., Christiaens, V., Poovathingal, S., Wouters, J., Aibar, S., & Aerts, S. (2023) · Nature Methods · doi:10.1038/s41592-023-01938-4 · Cited by 778
Self-citationToward Minimal Residual Disease-Directed Therapy in Melanoma
Rambow, F., Rogiers, A., Marin-Bejar, O., Aibar, S., Femel, J., Dewaele, M., Karras, P., Brown, D., Chang, Y. H., Debiec-Rychter, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.025 · Cited by 771
Self-citationMelanoma addiction to the long non-coding RNA SAMMSON
Leucci, E., Vendramin, R., Spinazzi, M., Laurette, P., Fiers, M., Wouters, J., Radaelli, E., Eyckerman, S., Leonelli, C., Vanderheyden, K., et al. (2016) · Nature · doi:10.1038/nature17161 · Cited by 582
Self-citationcisTopic: cis-regulatory topic modeling on single-cell ATAC-seq data
Bravo González-Blas, C., Minnoye, L., Papasokrati, D., Aibar, S., Hulselmans, G., Christiaens, V., Davie, K., Wouters, J., & Aerts, S. (2019) · Nature Methods · doi:10.1038/s41592-019-0367-1 · Cited by 456
Self-citationPan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity
Kinker, G. S., Greenwald, A. C., Tal, R., Orlova, Z., Cuoco, M. S., McFarland, J. M., Warren, A., Rodman, C., Roth, J. A., Bender, S. A., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00726-6 · Cited by 445
YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers
Stein, C., Bardet, A. F., Roma, G., Bergling, S., Clay, I., Ruchti, A., Agarinis, C., Schmelzle, T., Bouwmeester, T., Schübeler, D., et al. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005465 · Cited by 414
Phenotype plasticity as enabler of melanoma progression and therapy resistance
Arozarena, I., & Wellbrock, C. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0154-4 · Cited by 381
The AP-1 transcriptional complex: Local switch or remote command?
Bejjani, F., Evanno, E., Zibara, K., Piechaczyk, M., & Jariel-Encontre, I. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.003 · Cited by 352
Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis
Hanniford, D., Ulloa-Morales, A., Karz, A., Berzoti-Coelho, M. G., Moubarak, R. S., Sánchez-Sendra, B., Kloetgen, A., Davalos, V., Imig, J., Wu, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.007 · Cited by 349
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
Rambow, F., Marine, J.-C., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 325
Self-citationRegulation of the Hippo Pathway Transcription Factor TEAD
Lin, K. C., Park, H. W., & Guan, K.-L. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.09.003 · Cited by 332
Intratumor and Intertumor Heterogeneity in Melanoma
Grzywa, T. M., Paskal, W., & Włodarski, P. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.09.007 · Cited by 299
Many ways to resistance: How melanoma cells evade targeted therapies
Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 270
Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma
Wouters, J., Kalender-Atak, Z., Minnoye, L., Spanier, K. I., De Waegeneer, M., Bravo González-Blas, C., Mauduit, D., Davie, K., Hulselmans, G., Najem, A., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0547-3 · Cited by 258
Self-citationCodon-specific translation reprogramming promotes resistance to targeted therapy
Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0243-7 · Cited by 271
Self-citationA cellular hierarchy in melanoma uncouples growth and metastasis
Karras, P., Bordeu, I., Pozniak, J., Nowosad, A., Pazzi, C., Van Raemdonck, N., Landeloos, E., Van Herck, Y., Pedri, D., Bervoets, G., et al. (2022) · Nature · doi:10.1038/s41586-022-05242-7 · Cited by 247
Self-citationFalletta, P., Sanchez-del-Campo, L., Chauhan, J., Effern, M., Kenyon, A., Kershaw, C. J., Siddaway, R., Lisle, R., Freter, R., Daniels, M. J., et al. (2017) · Genes & Development · doi:10.1101/gad.290940.116 · Cited by 239
Tead and AP1 Coordinate Transcription and Motility
Liu, X., Li, H., Rajurkar, M., Li, Q., Cotton, J. L., Ou, J., Zhu, L. J., Goel, H. L., Mercurio, A. M., Park, J.-S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.104 · Cited by 234
Riesenberg, S., Groetchen, A., Siddaway, R., Bald, T., Reinhardt, J., Smorra, D., Kohlmeyer, J., Renn, M., Phung, B., Aymans, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms9755 · Cited by 227
The journey from melanocytes to melanoma
Centeno, P. P., Pavet, V., & Marais, R. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00565-7 · Cited by 197
Laurette, P., Strub, T., Koludrovic, D., Keime, C., Le Gras, S., Seberg, H., Van Otterloo, E., Imrichova, H., Siddaway, R., Aerts, S., et al. (2015) · eLife · doi:10.7554/elife.06857 · Cited by 199
Self-citationi-cisTarget 2015 update: generalized cis-regulatory enrichment analysis in human, mouse and fly
Imrichová, H., Hulselmans, G., Kalender Atak, Z., Potier, D., & Aerts, S. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv395 · Cited by 202
“Collections of human and mouse CRRs were also scored by the regulatory features: DHS, FAIRE, TF and histone ChIP-seq from ENCODE (15), Roadmap Epigenomics Project (28), data generated by Taipale laboratory (29), Aerts laboratory (H3K27ac, H3K27me3, FAIRE and MITF ChIP-seq on short-term melanoma cultures generated in-h…”
MethodSelf-citationA TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.037 · Cited by 199
Self-citationShaffer, S. M., Emert, B. L., Reyes Hueros, R. A., Cote, C., Harmange, G., Schaff, D. L., Sizemore, A. E., Gupte, R., Torre, E., Singh, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.003 · Cited by 194
Cell-type-directed design of synthetic enhancers
Taskiran, I. I., Spanier, K. I., Dickmänken, H., Kempynck, N., Pančíková, A., Ekşi, E. C., Hulselmans, G., Ismail, J. N., Theunis, K., Vandepoel, R., et al. (2024) · Nature · doi:10.1038/s41586-023-06936-2 · Cited by 175
Self-citationPearson, J. D., Huang, K., Pacal, M., McCurdy, S. R., Lu, S., Aubry, A., Yu, T., Wadosky, K. M., Zhang, L., Wang, T., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.016 · Cited by 175
YAP/TAZ Activation as a Target for Treating Metastatic Cancer
Warren, J., Xiao, Y., & Lamar, J. (2018) · Cancers · doi:10.3390/cancers10040115 · Cited by 164
Genome‐wide cooperation of EMT transcription factor ZEB 1 with YAP and AP ‐1 in breast cancer
Feldker, N., Ferrazzi, F., Schuhwerk, H., Widholz, S. A., Guenther, K., Frisch, I., Jakob, K., Kleemann, J., Riegel, D., Bönisch, U., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103209 · Cited by 165
Reinhardt, J., Landsberg, J., Schmid-Burgk, J. L., Ramis, B. B., Bald, T., Glodde, N., Lopez-Ramos, D., Young, A., Ngiow, S. F., Nettersheim, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0395 · Cited by 169
Brown, D. V., Filiz, G., Daniel, P. M., Hollande, F., Dworkin, S., Amiridis, S., Kountouri, N., Ng, W., Morokoff, A. P., & Mantamadiotis, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172791 · Cited by 172
Song, C., Piva, M., Sun, L., Hong, A., Moriceau, G., Kong, X., Zhang, H., Lomeli, S., Qian, J., Yu, C. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0401 · Cited by 158
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch
Kong, X., Kuilman, T., Shahrabi, A., Boshuizen, J., Kemper, K., Song, J., Niessen, H. W. M., Rozeman, E. A., Foppen, M. H. G., Blank, C. U., et al. (2017) · Nature · doi:10.1038/nature24037 · Cited by 155
Vivas, Y., Falletta, P., Liebing, J., Louphrasitthiphol, P., Feng, Y., Chauhan, J. S., Scott, D. A., Glodde, N., Chocarro‐Calvo, A., Bonham, S., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.10.014 · Cited by 157
Choi, J., Zhang, T., Vu, A. H., Ablain, J., Makowski, M. M., Colli, L. M., Xu, M., Hennessey, R. C., Yin, J., Rothschild, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16590-1 · Cited by 151
Microenvironment-derived factors driving metastatic plasticity in melanoma
Kim, I. S., Heilmann, S., Kansler, E. R., Zhang, Y., Zimmer, M. A., Ratnakumar, K., Bowman, R. L., Simon-Vermot, T., Fennell, M., Garippa, R. J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14343 · Cited by 142
ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
Richard, G., Dalle, S., Monet, M., Plaschka, M., Boespflug, A. M., Pommier, R. M., de la Fouchardière, A., Perier‐Muzet, M., Depaepe, L., Barnault, R., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505971 · Cited by 152
Epithelial‐to‐mesenchymal‐like transition events in melanoma
Pedri, D., Karras, P., Landeloos, E., Marine, J., & Rambow, F. (2021) · FEBS Journal · doi:10.1111/febs.16021 · Cited by 151
Self-citationEZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation
Zingg, D., Debbache, J., Peña‐Hernández, R., Antunes, A. T., Schaefer, S. M., Cheng, P. F., Zimmerli, D., Häusel, J., Calçada, R. R., Tuncer, E., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.001 · Cited by 145
Epigenetics of malignant melanoma
Moran, B., Silva, R., Perry, A. S., & Gallagher, W. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.006 · Cited by 142
Harnessing BET Inhibitor Sensitivity Reveals AMIGO2 as a Melanoma Survival Gene
Fontanals-Cirera, B., Hasson, D., Vardabasso, C., Micco, R. D., Agrawal, P. K., Chowdhury, A. H., Gantz, M., de Pablos-Aragoneses, A., Morgenstern, A., Wu, P., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.004 · Cited by 138
Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing
Miskolczi, Z., Smith, M. P., Rowling, E. J., Ferguson, J., Barriuso, J., & Wellbrock, C. (2018) · Oncogene · doi:10.1038/s41388-018-0209-0 · Cited by 135
Köhler, C., Nittner, D., Rambow, F., Radaelli, E., Stanchi, F., Vandamme, N., Baggiolini, A., Sommer, L., Berx, G., van den Oord, J. J., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.08.003 · Cited by 126
Self-citationReversal of pre-existing NGFR-driven tumor and immune therapy resistance
Boshuizen, J., Vredevoogd, D. W., Krijgsman, O., Ligtenberg, M. A., Blankenstein, S. A., de Bruijn, B., Frederick, D. T., Kenski, J. C. N., Parren, M., Brüggemann, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17739-8 · Cited by 127
Failed Apoptosis Enhances Melanoma Cancer Cell Aggressiveness
Berthenet, K., Ferrer, C. C., Fanfone, D., Popgeorgiev, N., Neves, D., Bertolino, P., Gibert, B., Hernández‐Vargas, H., & Ichim, G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107731 · Cited by 122
Seberg, H., Otterloo, E. V., & Cornell, R. A. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12611 · Cited by 136
Cross-species analysis of enhancer logic using deep learning
Minnoye, L., Taskiran, I. I., Mauduit, D., Fazio, M., Van Aerschot, L., Hulselmans, G., Christiaens, V., Makhzami, S., Seltenhammer, M., Karras, P., et al. (2020) · Genome Research · doi:10.1101/gr.260844.120 · Cited by 116
Self-citationImmunoediting instructs tumor metabolic reprogramming to support immune evasion
Tsai, C., Chuang, Y., Li, X., Yu, Y.-R., Tzeng, S., Teoh, S. T., Lindblad, K. E., Matteo, M. D., Cheng, W.-C., Hsueh, P., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2022.12.003 · Cited by 126
Ostrowski, S. M., & Fisher, D. E. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.08.010 · Cited by 148
NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF
Fane, M. E., Chhabra, Y., Hollingsworth, D. E. J., Simmons, J. L., Spoerri, L., Oh, T. G., Chauhan, J. S., Chin, T., Harris, L., Harvey, T. J., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.013 · Cited by 114
Focus on cutaneous and uveal melanoma specificities
Pandiani, C., Béranger, G. E., Leclerc, J., Ballotti, R., & Bertolotto, C. (2017) · Genes & Development · doi:10.1101/gad.296962.117 · Cited by 118
SCENIC+: single-cell multiomic inference of enhancers and gene regulatory networks
González-Blas, C. B., De Winter, S., Hulselmans, G., Hecker, N., Matetovici, I., Christiaens, V., Poovathingal, S., Wouters, J., Aibar, S., & Aerts, S. (2022) · doi:10.1101/2022.08.19.504505 · Cited by 778
Self-citationA non-coding function of TYRP1 mRNA promotes melanoma growth
Gilot, D., Migault, M., Bachelot, L., Journé, F., Rogiers, A., Donnou‐Fournet, E., Mogha, A., Mouchet, N., Pinel‐Marie, M., Mari, B. P., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3623 · Cited by 114
Self-citationTang, Y., Durand, S., Dalle, S., & Caramel, J. (2020) · Cancers · doi:10.3390/cancers12082154 · Cited by 120
Rathore, M. G., Girard, C. A. J., Ohanna, M., Tichet, M., Jouira, R. B., García, E., Larbret, F., Gesson, M., Audebert, S., Lacour, J. ‐., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0848-9 · Cited by 104
ZEB1 transcription factor promotes immune escape in melanoma
Plaschka, M., Benboubker, V., Grimont, M., Berthet, J., Tonon, L., Lopez, J., Bouar, M. L., Balme, B., Tondeur, G., de la Fouchardière, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003484 · Cited by 109
Corre, S., Tardif, N., Mouchet, N., Leclair, H. M., Boussemart, L., Gautron, A., Bachelot, L., Perrot, A., Soshilov, A. A., Rogiers, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06951-2 · Cited by 103
Self-citationThe Stress-Like Cancer Cell State Is a Consistent Component of Tumorigenesis
Baron, M., Tagore, M. M., Hunter, M. V., Kim, I. S., Moncada, R. M., Yan, Y., Campbell, N. R., White, R. M., & Yanai, I. (2020) · Cell Systems · doi:10.1016/j.cels.2020.08.018 · Cited by 108
Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma
Capparelli, C., Purwin, T. J., Glasheen, M. Q., Caksa, S., Tiago, M., Wilski, N. A., Pomante, D., Rosenbaum, S. R., Nguyen, M. Q., Cai, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28801-y · Cited by 109
Faião‐Flores, F., Alves-Fernandes, D. K., Pennacchi, P. C., Sandri, S., Vicente, A. L. S. A., Scapulatempo‐Neto, C., Vazquez, V. D. L., Reis, R. M., Chauhan, J. S., Goding, C. R., et al. (2016) · Oncogene · doi:10.1038/onc.2016.348 · Cited by 109
The emerging role of Hippo signaling pathway in regulating osteoclast formation
Yang, W., Han, W., Qin, A., Wang, Z., Xu, J., & Qian, Y. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26372 · Cited by 101
LncRNAs in human cancers: signal from noise
Adnane, S., Marino, A., & Leucci, E. (2022) · Trends in Cell Biology · doi:10.1016/j.tcb.2022.01.006 · Cited by 100
Vandamme, N., Denecker, G., Bruneel, K., Blancke, G., Akay, Ö., Taminau, J., Coninck, J. D., Smedt, E. D., Skrypek, N., Loocke, W. V., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2373 · Cited by 97
Self-citationWNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion
Rodríguez‐Hernández, I., Maiques, Ó., Kohlhammer, L., Cantelli, G., Perdrix-Rosell, A., Monger, J., Fanshawe, B., Bridgeman, V. L., Karagiannis, S. N., Penin, R. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18951-2 · Cited by 105
Ohanna, M., Cerezo, M., Nottet, N., Bille, K., Didier, R., Béranger, G. E., Mograbi, B., Rocchi, S., Yvan‐Charvet, L., Ballotti, R., et al. (2018) · Genes & Development · doi:10.1101/gad.305854.117 · Cited by 97
YAP and TAZ are essential for basal and squamous cell carcinoma initiation
Debaugnies, M., Sánchez‐Danés, A., Rorive, S., Raphaël, M., Liagre, M., Parent, M.-A., Brisebarre, A., Salmon, I. J., & Blanpain, C. (2018) · EMBO Reports · doi:10.15252/embr.201845809 · Cited by 103
Small genomic insertions form enhancers that misregulate oncogenes
Abraham, B. J., Hnisz, D., Weintraub, A. S., Kwiatkowski, N. P., Li, C. H., Li, Z., Weichert‐Leahey, N., Rahman, S., Liu, Y., Etchin, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14385 · Cited by 96
Rossi, A., Roberto, M., Panebianco, M., Botticelli, A., Mazzuca, F., & Marchetti, P. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172621 · Cited by 99
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation
Campbell, N. R., Rao, A. N., Hunter, M., Sznurkowska, M. K., Briker, L., Zhang, M., Baron, M., Heilmann, S., Déforet, M., Kenny, C., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.08.018 · Cited by 103
The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis
Zhang, X., Yang, L., Szeto, P., Abali, G. K., Zhang, Y., Kulkarni, A., Amarasinghe, K. C., Li, J., Vergara, I. A., Molania, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1362-9 · Cited by 116
Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma
Tomé-García, J., Erfani, P., Nudelman, G., Tsankov, A. M., Katsyv, I., Tejero, R., Zhang, B., Walsh, M. J., Friedel, R. H., Zaslavsky, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06258-2 · Cited by 98
Atkins, M., Potier, D., Romanelli, L., Jacobs, J., Mach, J., Hamaratoglu, F., Aerts, S., & Halder, G. (2016) · Current Biology · doi:10.1016/j.cub.2016.06.035 · Cited by 88
Self-citationMITF reprograms the extracellular matrix and focal adhesion in melanoma
Dilshat, R., Fock, V., Kenny, C., Gerritsen, I., Lasseur, R. M. J., Trávníčková, J., Eichhoff, O. M., Cerny, P., Möller, K., Sigurbjörnsdóttir, S., et al. (2021) · eLife · doi:10.7554/elife.63093 · Cited by 93
Multiplex enhancer-reporter assays uncover unsophisticated TP53 enhancer logic
Verfaillie, A., Svetlichnyy, D., Imrichova, H., Davie, K., Fiers, M., Kalender Atak, Z., Hulselmans, G., Christiaens, V., & Aerts, S. (2016) · Genome Research · doi:10.1101/gr.204149.116 · Cited by 82
Self-citationThe low affinity neurotrophin receptor CD271 regulates phenotype switching in melanoma
Restivo, G., Diener, J., Cheng, P. F., Kiowski, G., Bonalli, M., Biedermann, T., Reichmann, E., Levesque, M. P., Dummer, R., & Sommer, L. (2017) · Nature Communications · doi:10.1038/s41467-017-01573-6 · Cited by 82
Apoptosis – Fueling the oncogenic fire
Ferrer, C. C., Berthenet, K., & Ichim, G. (2020) · FEBS Journal · doi:10.1111/febs.15624 · Cited by 88
Kemper, K., Krijgsman, O., Kong, X., Cornelissen‐Steijger, P., Shahrabi, A., Weeber, F., Velden, D. L. V. D., Bleijerveld, O. B., Kuilman, T., Kluin, R. J. C., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.064 · Cited by 81
MITF controls the TCA cycle to modulate the melanoma hypoxia response
Louphrasitthiphol, P., Ledaki, I., Chauhan, J. S., Falletta, P., Siddaway, R., Buffa, F. M., Mole, D. R., Soga, T., & Goding, C. R. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12802 · Cited by 83
Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis
Hölzel, M., & Tüting, T. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.03.009 · Cited by 84
Ennen, M., Keime, C., Gambi, G., Kieny, A., Coassolo, S., Thibault-Carpentier, C., Margerin-Schaller, F., Davidson, G., Vagne, C., Lipsker, D. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0010 · Cited by 87
The MITF-SOX10 regulated long non-coding RNA DIRC3 is a melanoma tumour suppressor
Coe, E. A., Tan, J. Y., Shapiro, M., Louphrasitthiphol, P., Bassett, A. R., Marques, A. C., Goding, C. R., & Vance, K. W. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008501 · Cited by 82
The Hippo Pathway as a Driver of Select Human Cancers
Kulkarni, A., Chang, M. T., Vissers, J. H. A., Dey, A., & Harvey, K. F. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.04.004 · Cited by 81
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Smith, M. P., Rowling, E. J., Miskolczi, Z., Ferguson, J., Spoerri, L., Haass, N. K., Sloss, O., McEntegart, S., Arozarena, I., von Kriegsheim, A., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607156 · Cited by 77
Network-based approaches for modeling disease regulation and progression
Galindez, G., Sadegh, S., Baumbach, J., Kacprowski, T., & List, M. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.12.022 · Cited by 78
Girard, C. A. J., Lecacheur, M., Jouira, R. B., Berestjuk, I., Diazzi, S., Prod’homme, V., Mallavialle, A., Larbret, F., Gesson, M., Schaub, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2914 · Cited by 79
Self-citationA comparative analysis of chromatin accessibility in cattle, pig, and mouse tissues
Halstead, M. M., Kern, C., Saelao, P., Wang, Y., Chanthavixay, G., Medrano, J. F. F., Eenennaam, A. L. V., Korf, I. F., Tuggle, C. K., Ernst, C. W., et al. (2020) · BMC Genomics · doi:10.1186/s12864-020-07078-9 · Cited by 88
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma
Maitituoheti, M., Keung, E. Z.-Y., Tang, M., Liang, Y., Alam, H., Han, G., Singh, A. K., Raman, A. T., Terranova, C. J., Sarkar, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108293 · Cited by 90
Hammerlindl, H., & Schaider, H. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0435-1 · Cited by 75
Berestjuk, I., Lecacheur, M., Carminati, A., Diazzi, S., Rovera, C., Prod’homme, V., Ohanna, M., Popovic, A., Mallavialle, A., Larbret, F., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201911814 · Cited by 76
Tuning Transcription Factor Availability through Acetylation-Mediated Genomic Redistribution
Louphrasitthiphol, P., Siddaway, R., Loffreda, A., Pogenberg, V., Friedrichsen, H. J., Schepsky, A., Zeng, Z., Lu, M. M., Strub, T., Freter, R., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.025 · Cited by 69
Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy
Huang, F., Santinon, F., González, R. E. F., & Rincon, S. V. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756001 · Cited by 75
BRN 2, a POU erful driver of melanoma phenotype switching and metastasis
Fane, M. E., Chhabra, Y., Smith, A. G., & Sturm, R. A. (2018) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12710 · Cited by 71
Genetic progression of malignant melanoma
Tímár, J., Vízkeleti, L., Doma, V., Barbai, T., & Rásó, E. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9613-5 · Cited by 68
STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway
Swoboda, A., Soukup, R., Eckel, O., Kinslechner, K., Wingelhofer, B., Schörghofer, D., Sternberg, C., Pham, H. T. T., Vallianou, M., Horvath, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01584-6 · Cited by 68
Huang, F., Gonçalves, C., Bartish, M., Rémy-Sarrazin, J., Issa, M. E., Cordeiro, B., Guo, Q., Émond, A., Attias, M., Yang, W., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140752 · Cited by 69
Self-citationLoss of Ambra1 promotes melanoma growth and invasion
Leo, L. D., Bodemeyer, V., Bosisio, F. M., Claps, G., Carretta, M., Rizza, S., Faienza, F., Frías, A., Khan, S., Bordi, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22772-2 · Cited by 67
Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2023) · Oncogenesis · doi:10.1038/s41389-023-00452-8 · Cited by 70
Waaler, J., Mygland, L., Tveita, A. A., Strand, M. F., Solberg, N. T., Olsen, P. A., Aizenshtadt, A., Fauskanger, M., Lund, K., Brinch, S. A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0916-2 · Cited by 62
Metadata
- Authors
- Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., Christiaens, V., Svetlichnyy, D., Luciani, F., Van den Mooter, L., Claerhout, S., Fiers, M., Journe, F., Ghanem, G.-E., Herrmann, C., Halder, G., Marine, J.-C., & Aerts, S.
- Affiliations
- KU Leuven (BE)
- VIB-KU Leuven Center for Cancer Biology (BE)
- Université Libre de Bruxelles (BE)
- German Cancer Research Center (DE)
- Corresponding author
- Aerts, Stein
- ORCID
- Venue
- Nature Communications
- Published
- 2015-04-09
- Volume
- 6
- Issue
- 1
- Pages
- 6683-6683
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4403341
- OpenAlex
- W2018433132
- Cited by
- 489
- References
- 72
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 59 · 2023: 56 · 2022: 59 · 2021: 50 · 2020: 56 · 2019: 41 · 2018: 33 · 2017: 39 · 2016: 24 · 2015: 11
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (KU Leuven) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Funders
- Fonds Wetenschappelijk Onderzoek
- KU Leuven
- Kom op tegen Kanker
- Fondation contre le Cancer
- Stand Up To Cancer
- Bijzonder Onderzoeksfonds UGent
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- melanoma, cell invasion, transcriptional reprogramming, TEAD transcription factors, SOX10, MITF, AP-1, MAPK inhibitors, MAPK inhibitor resistance, chromatin accessibility, histone modifications, DNA methylation, metastasis
- MeSH terms
- TEA Domain Transcription Factors, Antineoplastic Agents, Cell Transformation, Neoplastic, Chromatin, DNA-Binding Proteins, Histones, Humans, Melanoma, Neoplasm Invasiveness, Nuclear Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Gene Expression Regulation, Neoplastic, Transcription Factor AP-1, DNA Methylation, Protein Isoforms, RNA, Small Interfering, Cell Line, Tumor, Protein Kinase Inhibitors, Microphthalmia-Associated Transcription Factor, Gene Regulatory Networks, SOXE Transcription Factors, Transcriptome, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.